

1 **Differential sensitivity to hypoxia enables shape-based classification of sickle cell disease and**
2 **trait blood samples**

3

4 Claudy D'Costa^{a,1}, Oshin Sharma^{a,1}, Riddha Manna^a, Minakshi Singh^a, Samrat^{a,b}, Srushti
5 Singh^{a,b}, Anish Mahto^a, Pratiksha Govil^a, Sampath Satti^a, Ninad Mehendale^a, Yazdi Italia^c and
6 Debjani Paul^{a,d,2}

7

8 ^aDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai,
9 Mumbai 400076, Maharashtra, India

10

11 ^bMedPrime Technologies Pvt. Ltd., Casa Piedade Co-operative Housing Society, Charai,
12 Thane – 400601, Maharashtra, India

13

14 ^cValsad Rakt dan Kendra, Valsad - 396001, Maharashtra, India.

15

16 ^dAssociate faculty, Wadhvani Research Centre for Bioengineering, Indian Institute of
17 Technology Bombay, Powai, Mumbai 400076, Maharashtra, India

18

19

20 ¹Equal contributions

21 ²To whom correspondence may be addressed: debjani.paul@iitb.ac.in; ORCID: 0000-0001-9281-
22 3516

23

24 Keywords: sickle cell anemia, hemoglobin polymerization, chemically-induced hypoxia,
25 microfluidics, smartphone microscopy, RBC shape, shape-based classifier

26

27 **Abstract**

28 Differentiating between homozygous (disease) and heterozygous (trait) sickle cell patients is the
29 key to ensuring appropriate long-term disease management. Well-equipped labs needed to perform
30 confirmatory diagnostic tests are not available in endemic areas of most low- and medium-income
31 countries. As a consequence of hemoglobin polymerization, red blood cells (RBCs) become sickle
32 shaped and stiff under hypoxic conditions in sickle cell anemia patients. A simple test such as
33 microscopy, using RBC shape as a biophysical marker, cannot conclusively differentiate between
34 homozygous (disease) and heterozygous (trait) sickle blood. Here, we establish a new paradigm
35 of microscopic diagnosis of sickle cell disease by exploiting differential polymerization of
36 hemoglobin in disease and trait RBCs under controlled, chemically-induced hypoxia in a
37 microfluidic chip. We use a portable smartphone microscope to compare the RBC shape
38 distributions in blood treated with high and low concentrations of the hypoxia-inducing agent to
39 correctly identify 35 blood samples as healthy, sickle cell disease or trait. Finally, we demonstrate
40 our test in remote field locations to enable fast and confirmed diagnosis of sickle cell anemia in
41 resource-limited areas.

42

43

44 Introduction


45 Sickle cell anemia is a genetic disorder caused by a glutamine to valine mutation in the β -globin
46 gene¹. It results in partial or complete replacement of normal adult hemoglobin (HbA) with
47 mutated sickle hemoglobin (HbS). HbS polymerizes under hypoxic conditions and forms rigid
48 and misshapen red blood cells (RBCs). The loss of deformability of RBCs leads to frequent vaso-
49 occlusive crisis, joint pain, spleen damage, increased susceptibility to infection and anemia. While
50 there is no cure available for sickle cell anemia, early diagnosis can prevent child mortality and
51 improve the quality of life of the affected individuals.

52 Sickle cell disease is widely prevalent in several parts of the world including western Africa, Latin
53 America, the Arab peninsula, and India². More than 500 children die of sickle cell anemia every
54 day due to lack of comprehensive newborn screening programs in low- and medium-income
55 countries (LMIC). Distinguishing between sickle cell disease (homozygous) and trait
56 (heterozygous) individuals is crucial to ensure appropriate clinical and non-clinical interventions.
57 The current two-step diagnosis protocol involves a solubility test to screen for HbS-positive
58 individuals, followed by hemoglobin electrophoresis or high-performance liquid chromatography
59 (HPLC) to distinguish between homozygous and heterozygous individuals³. The laboratory
60 infrastructure and trained personnel required for these tests are not always available in LMICs to
61 sustain countrywide screening programs⁴.

62 Preparation of blood smear slides and their microscopic examination are diagnostic techniques that
63 are relatively easier to administer in LMICs. Despite the widespread use of microscopy to study
64 sickle blood in the early days²⁻⁵, it is no longer a technique preferred by the clinicians. Sickle blood
65 has only 5% - 25% irreversibly sickled cells (ISCs)⁶, requiring extensive scanning of each smear
66 slide by a technician. While use of a chemical oxygen scavenger, such as sodium dithionate or
67 sodium metabisulphite, allows more RBCs to sickle *in vitro*, the process can take as long as 24
68 hours for trait blood samples. Most importantly, it is not possible to conclusively distinguish
69 between sickle cell disease and trait blood by simple visual inspection of RBC shapes.

70 Several research groups have explored image processing or machine learning techniques to study
71 RBC morphologies⁷⁻¹⁸. These techniques have focused on classification of individual RBC shapes
72 into normal (biconcave), sickle or abnormal (i.e. having any shape other than biconcave or sickle).
73 None of these reports have used RBC shape as a sole biophysical marker to classify sickle blood
74 samples into disease or trait. Recently, Javidi and others classified blood samples into healthy and
75 sickle based on membrane fluctuation analysis of individual RBCs¹⁹. De Haan *et al* developed a
76 mobile phone microscope to image blood smears, followed by automated identification of ISCs in
77 these images²⁰. As a shortcoming of their method, the authors stated that blood smears cannot be
78 used to identify sickle cell genotypes, i.e. to discriminate between trait and disease blood samples.
79 There is currently no test that uses RBC shape as a sole biophysical marker to classify sickle blood
80 samples into disease or trait.

81



82

83

84 *Figure 1. An assay to induce controlled sickling of RBCs inside a microfluidic chip, followed by imaging*
 85 *and analysis of RBC shapes. (A) A drop of blood is added to an oxygen scavenger ($\text{Na}_2\text{S}_2\text{O}_5$), introduced*
 86 *into a microfluidic chamber and sealed. We image the sample after 30 min and analyze the RBC shapes to*
 87 *obtain a characteristic roundness distribution. (B) Exploded view of the microfluidic chamber. The*
 88 *thickness of the spacer determines the height of the chamber. RBCs inside a 30 μm high chamber are*
 89 *oriented flat, while they are stacked and randomly oriented when the height is 80 μm . (C) A photo of the*
 90 *portable smartphone microscope designed and fabricated by us. (D) Number of healthy RBCs in the field*
 91 *of view (n_{FOV}) inside imaging chambers of different heights ($N = 7$). (E) The time taken (t_d) for the first*
 92 *RBC in the field of view to start sickling inside chips of different heights ($N = 6$). (F) The percentage of*
 93 *sickle cells (n_{sickle}) at $t = 30$ min inside chips of different heights ($N = 6$). The horizontal lines indicate the*
 94 *mean values in panels D-F.*

95

96 Here, we combine microfluidics, smartphone microscopy and image processing techniques (**figure**
 97 **1**) to develop a method that accurately distinguishes between disease and trait sickle blood based
 98 on the differential shape changes of RBCs when treated with two different concentrations of an
 99 oxygen scavenger, sodium metabisulphite. As shown in **figure 1A**, the method consists of mixing

100 a drop of blood with a specific concentration of sodium metabisulphite, loading it into a
101 microfluidic chip and imaging the sickled RBCs in real time using a smartphone microscope. The
102 roundness distributions of RBCs after 30 min are used to classify the blood sample as healthy,
103 disease or trait. The use of a microfluidic chip (**figure 1B**) as an imaging chamber instead of a
104 smear slide enables fast sickling and tracking of RBC shapes in real time. The chip is made of
105 glass to facilitate brightfield imaging of unstained RBCs using a mobile phone microscope and to
106 maintain hypoxic conditions inside the chamber for the duration of the experiment. We optimized
107 the height of the chamber to be 30 μm to avoid stacking of RBCs. We also designed and fabricated
108 a portable smartphone microscope (**figure 1C**) to conduct our experiments outside the laboratory
109 at sickle cell screening camps.

110 **Methods**

111 **Blood samples.** All studies using human blood samples were approved by the Institute Ethics
112 Committee (IEC), IIT Bombay, with approval numbers IITB-IEC/2016/016, IITB-IEC/2017/020
113 and IITB-IEC/2018/042. Leftover de-identified blood samples were collected from adults and
114 older children with a mix of genders during sickle cell screening camps organized by Shirin and
115 Jamshed Guzder Regional Blood Centre (Valsad, Gujarat) and Dayanand Hospital (Talasari,
116 Maharashtra). Written informed consent to use leftover blood samples was taken from all
117 participants. The ages of the participants ranged from 10 to 60 years. We excluded those
118 individuals who (i) were under treatment with folic acid or hydroxyurea, or (ii) received blood
119 transfusion within three months prior to blood collection. Blood samples from self-reported
120 healthy volunteers from IIT Bombay and Dayanand Hospital were used as healthy samples during
121 development and validation of the classifier. All known sickle blood samples ($D = 23$ and $T = 92$)
122 were first screened by the hospital personnel using a standard solubility test. Their hemoglobin
123 profiles were then confirmed using HPLC to conclusively identify them as disease or trait.

124 **Experiment protocol.** Blood samples collected in K3/EDTA vacutainer tubes were stored at 4°C.
125 All tests were performed either at IIT Bombay or in field locations within 48 h of blood collection.
126 Sodium metabisulphite solutions were freshly prepared in cell culture media (RPMI-1640) before
127 each experiment and discarded after 3 h. A drop of blood was added to 0.1% and/or 0.3% sodium
128 metabisulphite to dilute it by 20X, irrespective of hematocrit value. The average pH of blood mixed
129 with 0.1% and 0.3% sodium metabisulphite solution was 6.05 ± 0.2 and 5.83 ± 0.1 respectively. A
130 10 μl volume of 20X diluted blood mixed with an appropriate concentration of sodium
131 metabisulphite was introduced into the imaging chamber and the chip was sealed with quick-
132 drying transparent nail lacquer. This step was repeated if air bubbles got trapped in the sealed chip
133 or significant crenation occurred in RBCs immediately after loading. The chip was placed on the
134 sample stage of a smartphone microscope and images of RBCs were captured at 0 min and 30 min.
135 We also captured real-time videos of sickling for 30 min at 30 fps to understand the sickling
136 kinetics. While the ambient temperature in the lab ranged from 29°C to 31°C, the temperature
137 during field testing varied between 25°C and 32°C. High performance liquid chromatography

138 (HPLC) was performed at Shirin and Jamshed Guzder Regional Blood Centre on all sickle blood
139 samples to obtain their hemoglobin profiles (HbA, HBA₂, HbS and HbF).

140 **Mobile phone microscope.** We developed a battery-operated inverted transmission microscope to
141 capture images of unstained RBCs in the field. The microscope has a 1W white LED, fitted with
142 a collimating lens, as the illumination source and a single 40X (0.65 NA) air objective. The image
143 is focussed on the mobile phone camera by vertically moving the sample stage. We used Xiaomi
144 Mi3 or Samsung A10 mobile phones to capture images of RBCs with a minimum resolution of
145 2368 pixels × 4208 pixels. These phone models were chosen to balance performance, cost and
146 availability in developing countries. We developed one microscope model with a fixed phone
147 holder and another where the phone holder can be tilted by any angle for viewing comfort. The
148 sample stage and the base of the microscope are made of aluminium for increased stability, while
149 the remaining parts, including the outer body, are 3D-printed using PLA. Exploded images of the
150 mechanical and optical parts of the microscope can be seen in **figure S1** in supplementary
151 information.

152 **Image analysis and classification.** Brightfield images of unstained RBCs were analyzed by
153 ImageJ following a process flow shown in **figure S2** in the supporting information²¹. We measured
154 roundness and solidity of each RBC. RBCs with solidity <0.8 were excluded from analysis as these
155 corresponded to partially focused RBCs. Roundness values of remaining ~ 150 - 200 RBCs in the
156 field of view were binned into 10 groups with 0.1 width to obtain the roundness distribution. Each
157 distribution was normalized by dividing by the total number of RBCs included in the analysis. We
158 used R programming language²² to calculate connectivity and Dunn index for all 16 P₁ and P₂
159 combinations. The connectivity was calculated with 10 nearest neighbors. By applying a support
160 vector machine (SVM) model with a linear kernel and a cost of 10 on the raw data, we obtained a
161 classifier given by the equation: $y = -1.527x + 0.633$.

162 **Results and discussion**

163 **The optimized height the microfluidic imaging chamber is 30 μm**

164 We fabricated our imaging chambers using glass due to its non-permeability to oxygen and good
165 optical properties. We obtained different chamber heights (10 μm, 20 μm, 30 μm, 40 μm, 80 μm
166 and 100 μm) using double-sided adhesive films of specific thicknesses as spacers. An increase in
167 microfluidic confinement increased crenation of healthy RBCs. A chamber height of 80 μm or
168 above reduced crenation and promoted sickling, but led to stacking of RBCs. Therefore, we
169 focussed on chips of intermediate heights, e.g. 10, 20, 30 and 40 μm.

170 As shown in **figure 1D**, we counted the number of RBCs in the field of view (n_{FOV}) inside
171 chambers of different heights. Relatively fewer RBCs were present inside 10 μm (110 ± 10 ; mean
172 \pm SEM) and 20 μm (165 ± 23) high chambers. In contrast, the image processing algorithm detected
173 more than 200 RBCs inside chambers with 30 μm (268 ± 27) and 40 μm (213 ± 21) heights. The
174 number of RBCs detected inside the chamber increases with an increase in the chamber height. As

175 there are more densely packed RBCs inside the 40 μm high chamber, these are eliminated as
176 clusters by the image processing algorithm. This results in a decrease in the number of RBCs
177 counted by the algorithm inside the 40 μm high chamber.

178 As shown in **figure 1E**, we treated six sickle cell disease blood samples with 0.1% sodium
179 metabisulphite. From real time videos of sickling, we measured the time (t_d) it takes for the first
180 RBC in the field of view to sickle inside imaging chambers of different heights. A detailed
181 discussion on the delay time is given elsewhere in the paper. The values of t_d are 10.6 ± 0.5 min
182 (mean \pm SEM), 6.0 ± 1.2 min, 3.9 ± 0.6 min and 2.3 ± 0.5 min for chip heights of 10, 20, 30 and
183 40 μm respectively.


184 We also measured the percentage of sickled RBCs (n_{sickle}) at $t = 30$ min inside these chambers.
185 As shown in **figure 1F**, the mean value of n_{sickle} ranged from 58% to 75% with a large variability
186 in the data. We found that RBCs inside a 30 μm chamber do not crenate much and sickle relatively
187 fast ($t_d = 3.9 \pm 0.6$ min). On an average, there are > 250 RBCs in the field of view. Therefore, all
188 further experiments in this study were conducted inside 30 μm chambers.

189 **Difference in polymerization of sickle hemoglobin in disease and trait blood leads to different** 190 **RBC shapes**

191 I. J. Sherman first connected the shapes of sickled RBCs to the rate of oxygen removal by noting
192 that slow deoxygenation resulted in RBCs with sickle shapes, while sudden deoxygenation made
193 them granular. He reported that disease blood had more sickled RBCs in it compared to trait blood⁶.
194 A relation between RBC shapes and polymerization kinetics of sickle hemoglobin (HbS) was later
195 proposed by Eaton and Hofrichter. Based on extensive *in vitro* studies on HbS, they predicted that
196 sickle shapes of RBCs are likely to result from the growth of a single polymer domain during slow
197 polymerization. Presence of multiple small polymer domains with shorter fibers should lead to
198 holly leaf cell shapes. When there are many more randomly oriented and very short fibers, RBCs
199 become granular²³. Direct experimental evidence of this prediction using linear dichroism
200 microscopy was provided by Mickols *et al*²⁴ and by Corbett *et al*²⁵. They measured the distribution
201 and orientation of aligned hemoglobin polymer domains inside RBCs and related it to different
202 cell shapes.

203 **Figure 2** schematically illustrates different HbS polymerization mechanisms in disease and trait
204 blood and the associated RBC shapes. The total hemoglobin in homozygous sickle blood consists
205 of 95% - 98% HbS, 2% - 3% HbA₂ (another variant of normal hemoglobin) and 2% HbF (fetal
206 hemoglobin). Heterozygous sickle cell blood contains 35% - 45% HbS, 50% - 65% HbA, 2% - 3%
207 HbA₂ and $\sim 2\%$ HbF²⁶. As shown in **figure 2A**, blood from healthy individuals has HbAA
208 homodimers ($\alpha_2\beta_2$), sickle cell disease blood has HbSS homodimers ($\alpha_2\beta^S_2$), and trait blood
209 contains a mix of HbAA homodimers ($\alpha_2\beta_2$), HbSS homodimers ($\alpha_2\beta^S_2$) and HbAS heterodimers
210 ($\alpha_2\beta\beta^S$).

211 According to the double nucleation model proposed by Ferrone *et al*, hemoglobin polymerization
 212 can proceed by homogenous or heterogeneous nucleation (**figure 2B**)²⁷. Homogeneous nucleation
 213 involves growth of independent polymer chains from HbS molecules in solution, whereas
 214 heterogeneous nucleation involves formation of branches on already existing polymers. Even
 215 though homogeneous nucleation is thermodynamically less favorable, Ferrone and others



216


217 *Figure 2. Schematic diagram relating hemoglobin polymerization mechanism to the shapes of sickled RBCs.*
 218 *(A) Hemoglobin in healthy blood exists as homodimer AA ($\alpha_2\beta_2$). This homodimer is also found in trait*
 219 *blood. Sickle hemoglobin can either form a homodimer SS ($\alpha_2\beta^S_2$), found in both trait and disease blood,*
 220 *or a heterodimer AS ($\alpha_2\beta\beta^S$) with normal hemoglobin, found only in trait blood. (B) During hemoglobin*
 221 *polymerization, homogeneous nucleation leads to one or more non-branched polymer chains, while*
 222 *heterogeneous nucleation leads to branched polymers. The kind of hemoglobin polymerization that takes*
 223 *place inside an RBC affects its shape. (C) A pictorial summary of how shapes of sickled RBCs depend on*
 224 *HbS concentration and deoxygenation rate. Green ‘up triangle’ symbol indicates a high HbS concentration*
 225 *or fast deoxygenation. Red ‘down triangle’ symbol indicates low HbS concentration or slow deoxygenation.*

226 suggested that it can be sustained in samples with high initial HbS concentration for a longer
 227 duration before heterogeneous nucleation takes over. Since sickle cell disease blood has high HbS
 228 concentration, it follows that these samples are likely to sustain homogeneous nucleation for longer.
 229 The authors further observed that fast deoxygenation leads to more homogeneous nucleation sites
 230 and formation of randomly oriented polymer chains. Hence, we expect that faster deoxygenation
 231 in disease samples would lead to more granular RBCs, and very few, if any, sickle-shaped RBCs.
 232 Slow deoxygenation in these samples would lead to sickle RBCs, resulting from sustained

233 homogeneous nucleation, as well as some holly leaf and granular RBCs formed due to
 234 heterogeneous nucleation.

235 In addition to HbS concentration and the rate of deoxygenation, HbS polymerization in trait
 236 samples is also affected by the presence of HbAS heterodimers which can constitute as much as ~
 237 49% mole fraction of the total hemoglobin²⁸. HbS concentration in trait samples is too low to
 238 sustain homogeneous nucleation. Moreover, HbAS heterodimers have a lower probability to take
 239 part in polymerization compared to HbSS homodimers²⁹. Under slow deoxygenation, due to a lack
 240 of nucleation sites, RBC morphology in trait blood appears to be unchanged. When deoxygenation
 241 is rapid, trait RBCs deform into primarily holly leaf shapes resulting from heterogeneous
 242 nucleation. **Figure 2C** summarizes the combined effect of HbS concentration and rate of
 243 deoxygenation on RBC shapes. Our shape-based classification method to identify unknown blood
 244 samples makes use of the variation in RBC shapes in disease and trait samples in response to slow
 245 and fast deoxygenation.

246 Specific concentrations of sodium metabisulphite can lead to slow and fast deoxygenation



247
 248 *Figure 3. Optimization of sodium metabisulphite concentration to induce slow and fast deoxygenation in*
 249 *disease and trait blood samples. (A) Decrease in the dissolved oxygen in cell culture media (RPMI-1640)*
 250 *with time for different concentrations of sodium metabisulphite. (B) Schematic representation of the time*
 251 *(t_d) taken by the first unsickled RBC (enclosed by the black circle) in the field of view to sickle. Irreversibly*
 252 *sickled RBCs are encircled in dashed red. (C) t_d as a function of sodium metabisulphite concentration in*
 253 *three distinct disease and three distinct trait samples, represented as mean ± SEM (N = 3). (D) Number of*
 254 *sickled RBCs in disease (N = 4) and trait (N = 4) samples treated with 0.1% and 0.3% sodium*
 255 *metabisulphite respectively. The horizontal lines indicate the mean values in all the plots in (C) and (D).*

256 We optimized the concentration (w/v) of sodium metabisulphite with the goal of identifying two
257 specific concentrations at which disease and trait samples are likely to undergo slow and fast
258 deoxygenation resulting in different RBC shapes. **Figure 3A** shows a plot of the dissolved oxygen
259 content as a function of time for different concentrations of sodium metabisulphite. For the entire
260 range of concentrations studied, the oxygen content decreased to <5% within 30 min, which is
261 considered to be the physiological level of deoxygenation in blood³⁰.

262 We then mixed 0.1% to 0.5% sodium metabisulphite solutions with disease and trait blood samples
263 (**table S1** and **figure S3** in supporting information). We recorded real time sickling videos in our
264 smartphone microscope, and from the extracted frames, determined the instant (t_d) at which the
265 first unsickled RBC in the field of view starts sickling. **Figure 3B** shows how t_d is measured for
266 the RBC indicated by the solid black circle, with the first frame in the video taken as the timepoint
267 $t = 0$ min. RBCs inside the dashed red circles are already sickled, and therefore, are not considered
268 for this purpose.


269 We then used t_d as a parameter to compare the sickling behavior of disease and trait RBCs treated
270 with different sodium metabisulphite concentrations. **Figure 3C** shows how t_d varies with sodium
271 metabisulphite concentration for three disease and three trait samples. For disease samples treated
272 with 0.1%, 0.2% and 0.3% concentrations, t_d is $4.1 \text{ min} \pm 0.9 \text{ min}$ (mean \pm SEM), $1.7 \pm 0.4 \text{ min}$
273 and $1.3 \pm 0.3 \text{ min}$ respectively. The corresponding values for trait samples are $33.4 \pm 4.8 \text{ min}$, 4.5
274 $\pm 1.5 \text{ min}$ and $2.8 \pm 1.3 \text{ min}$ respectively. Since sickling occurs almost instantaneously at 0.4% and
275 0.5% concentrations, making it difficult to accurately measure t_d , these two concentrations were
276 not considered further.

277 While $82 \pm 3 \%$ (mean \pm SEM) of RBCs in disease blood sickle within 30 min when treated with
278 0.1 % concentration, only $21 \pm 3\%$ of RBCs in trait blood sickle at this concentration (**figure 3D**).
279 In contrast, the average number of sickled RBCs in disease and trait blood samples treated with
280 0.3% sodium metabisulphite for 30 min are $88 \pm 3 \%$ and $76 \pm 5\%$ respectively.

281 Therefore, based on the differential sickling response of RBCs in our experiments, we chose 0.1%
282 and 0.3% as the two sodium metabisulphite concentrations to induce slow and fast deoxygenation
283 respectively in sickle blood samples. The experiments on quantifying the shape distribution of
284 RBCs were performed with these two sodium metabisulphite concentrations.

285 **Deoxygenated healthy, disease and trait blood have characteristic roundness distributions**

286 We treated three samples each of healthy, disease and trait blood with 0.1% and 0.3% sodium
287 metabisulphite and imaged the RBCs after 30 min. Images of RBCs in the same blood samples,
288 without addition of the oxygen scavenger, were used as negative controls. **Figure 4A** shows
289 snippets of representative images from healthy, disease and trait blood samples, while the shapes
290 of individual sickled RBCs are shown in **figure 4B**. The complete raw images from which the
291 snippets are taken are shown in **figure S4** in the supporting information.



292

293 *Figure 4. Roundness as a shape descriptor for quantifying RBC shapes in healthy and sickle blood. (A)*
 294 *Snippets of representative images of healthy, disease and trait samples treated with 0.1% and 0.3% sodium*
 295 *metabisulphite for 30 min are shown. Some crenated RBCs are seen in both the healthy samples and the*
 296 *trait blood sample treated with 0.1% sodium metabisulphite. (B) Sickle RBCs under hypoxia have a range*
 297 *of shapes which can be characterized by a roundness value. (C) Distribution of different kinds of RBC*
 298 *shapes in deoxygenated disease (N = 3) and trait (N = 3) treated with 0.1% and 0.3% sodium*
 299 *metabisulphite. The horizontal lines indicate the mean values. (D) Roundness distributions of RBCs in*
 300 *healthy (H; black square), disease (D; red circle) and trait (T; blue triangle) samples treated with 0%,*
 301 *0.1% and 0.3% sodium metabisulphite respectively are shown. Each distribution is generated by analysing*
 302 *three different blood samples (N = 3) and then pooling the data to see the overall trend. Here, n indicates*
 303 *the total number of RBCs in three samples used to generate each roundness distribution plot. Each plot is*
 304 *normalized by dividing it by the number of RBCs (n).*

305 An experienced user then manually annotated and counted the number of sickle-shaped, holly leaf-
306 shaped, granular, and unsickled RBCs in each of these disease and trait images. **Figure S5** in
307 supporting information shows a typical annotated image. Since we found that the presence of
308 crenated RBCs leads to image artifacts, we also accounted for these RBCs in each sample. RBCs
309 which could not be classified into any of these categories were marked as ‘uncategorised’. As
310 shown in **figure 4C**, disease samples treated with 0.1% sodium metabisulphite have primarily a
311 mix of sickle ($34 \pm 6\%$; mean \pm SEM), holly leaf ($37 \pm 9\%$) and granular ($18 \pm 3\%$) RBCs. The
312 same samples, when treated with 0.3% concentration, have primarily granular ($80 \pm 11\%$) and a
313 few holly leaf ($14 \pm 7\%$) RBCs. Trait samples treated with 0.1% metabisulphite have ($76 \pm 4\%$)
314 unsickled RBCs. These samples have ($19 \pm 2\%$) sickle, ($60 \pm 3\%$) holly leaf and ($15 \pm 3\%$) granular
315 RBCs when treated with 0.3% metabisulphite concentration.

316 Wheelless *et al* identified ‘form factor’ (FF), given by equation (1), to be the best image analysis
317 feature to distinguish between sickle RBC shapes after comparing 42 shape descriptors³¹. As
318 shown in **figure S6** in the supporting information, ‘roundness’ (R), given by equation (2), is a
319 better measure of RBC shapes in our images than form factor.

320
$$FF = \frac{4 \times \pi \times Area}{Perimeter^2} \quad (1)$$

321
$$R = \frac{4 \times Area}{\pi \times Major\ axis^2} \quad (2)$$

322 **Figure 4D** shows the roundness distribution plots of RBCs in healthy (indicated by black square),
323 disease (red circle) and trait (blue triangle) blood, where each curve has data pooled from three
324 samples. Here, n indicates the number of RBCs from these three samples used to generate each
325 distribution plot. The left panel shows the control distributions in absence of the oxygen scavenger.
326 The distribution corresponding to healthy blood peaks at 1.0 as healthy biconcave RBCs lying flat
327 inside the imaging chamber appear circular in shape. The distributions for untreated trait and
328 disease samples peak at 0.9 due to the presence of very few ISCs. The disease distribution has a
329 broader peak compared to the trait distribution as disease samples have more ISCs than trait
330 samples.


331 The middle panel shows the roundness distributions of blood samples treated with 0.1% sodium
332 metabisulphite. Healthy RBCs show a peak at 0.9 – 1.0 as these do not sickle when treated with
333 an oxygen scavenger. Due to a combination of slower deoxygenation and high HbS concentration,
334 RBCs in disease samples have a mix of sickle, holly leaf and granular shapes, resulting in a broad
335 distribution with a peak at 0.5. The shapes of most RBCs in trait blood samples treated with 0.1%
336 sodium metabisulphite remain unchanged owing to the combined effect of fewer nucleation sites,
337 HbAS heterodimers, and slow deoxygenation. As a result, the roundness distribution peaks at 0.9,
338 similar to healthy RBCs.

339 The right panel shows roundness distributions of RBCs treated with 0.3% sodium metabisulphite.
340 A combination of faster deoxygenation and higher HbS concentration in disease samples results in

341 granular RBCs, which is reflected in a broad distribution with a peak at 0.7. On the other hand,
 342 owing to faster deoxygenation and lower HbS concentration, RBCs assume holly leaf shapes in
 343 trait samples. This leads to a somewhat bimodal roundness distribution with peaks at 0.6 and 0.8
 344 respectively. As expected, the distribution for healthy RBCs has a peak at 0.9. The tails of the
 345 distributions for healthy RBCs at lower roundness values in all three panels result from certain
 346 analysis artifacts, as shown in **figure S7** in the supporting information.

347 As RBCs with holly leaf and granular shapes have similar roundness values, the roundness
 348 distributions of trait and disease samples treated with 0.3% sodium metabisulphite overlap with
 349 each other. Similarly, the peaks of roundness distributions corresponding to healthy and trait
 350 samples treated with 0.1% sodium metabisulphite overlap.

351 A shape-based classifier distinguishes between healthy and sickle blood



352 *Figure 5. Derivation of two secondary shape parameters P_1 and P_2 from the roundness distributions. (A)*
 353 *Schematic diagram describing the process flow to choose a robust combination of P_1 and P_2 . (B) A plot of*
 354 *Dunn index vs connectivity for 16 unique combinations of P_1 and P_2 corresponding to 164 blood samples.*
 355 *The top-right quadrant of the plot indicates the most robust combinations (e.g. 10 and 12) with low*
 356 *connectivity and high Dunn index values. (C) Development of the classifier. P_2 vs P_1 data for 164 distinct*
 357 *blood samples with known haemoglobin profiles are plotted. Two distinct clusters are seen, one for the*
 358 *normal samples (HbA), and one for the trait and diseased samples (HbS). The classifier (dotted line)*
 359 *separates the parameter space into two regions indicated in grey and white.*

360 We derived two secondary shape parameters P_1 and P_2 from each roundness distribution, using a
361 process flow shown schematically in **figure 5A**. We identified two specific areas under each
362 roundness distribution curve by placing two contiguous windows of equal width (left panel). We
363 called these two areas parameter 1 (P_1 ; violet) and parameter 2 (P_2 ; green) respectively. Each
364 roundness distribution is represented as a single point on a plot of P_2 vs. P_1 . We then translated the
365 pair of windows by increments of 0.1 over the entire range of roundness values, while also varying
366 their widths from 0.2 to 0.5, and calculated all sixteen $P_1 - P_2$ combinations resulting from this
367 operation (middle panel). Widths <0.2 were not considered as they would contain information
368 about very few RBCs. We then ran a k-means algorithm on each of these 16 datasets to distinguish
369 between healthy and sickle (e.g. disease and trait) clusters. The optimal $P_1 - P_2$ combination was
370 identified using connectivity and Dunn index. Connectivity indicated how strongly two clusters
371 were connected, while Dunn index indicated intra-cluster compactness and inter-cluster
372 separation³². We finally plotted Dunn index vs. connectivity to identify the most robust
373 combination with low connectivity and high Dunn index (right panel) lying in the top right
374 quadrant of the plot.

375 **Figure 5B** shows a plot of Dunn index vs. connectivity for 16 $P_1 - P_2$ combinations generated
376 from the roundness distributions of 164 blood samples (H = 49, D = 23 and T = 92) with known
377 hemoglobin profiles. The values of the parameters used in this plot are given in **table S2** in the
378 supporting information. For this experiment, we treated disease samples with 0.1% sodium
379 metabisulphite as the roundness distributions of disease and trait samples are different at this
380 concentration. Similarly, both trait and healthy samples were treated with 0.3% sodium
381 metabisulphite to distinguish them from each other.

382 There are two points in the top right quadrant corresponding to the roundness ranges of 0.2 – 0.8
383 (combination #10; P_1 : 0.2 – 0.5; P_2 : 0.5 – 0.8) and 0.4 – 1.0 (combination #12, P_1 : 0.4 –
384 0.7; P_2 : 0.7 – 1.0) respectively that meet the selection criteria. Combination #10 includes
385 information about sickle RBCs with $0.2 < R < 0.4$ and excludes information about unsickled RBCs
386 with $R > 0.8$. Combination #12, with the highest Dunn index, lacks information about sickle RBCs
387 with $R < 0.4$, but includes information about unsickled RBCs with $R > 0.8$. As combination #10
388 contains information about RBCs that are physiologically more relevant to our study, we preferred
389 it over combination #12.


390 **Figure 5C** shows the P_2 vs. P_1 plot of 164 known samples corresponding to the first combination.
391 We used a support vector machine (SVM) model on this dataset to develop a classifier shown by
392 the dotted line that distinguished between healthy and sickle (e.g., both disease and trait) blood. A
393 point that lies in the grey parameter space below the classifier should correspond to a blood sample
394 with unsickled RBCs, while a point that lies in the white parameter space above the classifier
395 should correspond to a blood sample with sickled RBCs.

396

397

398 Distinguishing between disease and trait blood using our classifier

399 Based on our analysis, we proposed the work flow shown in **figure 6A** to classify an unknown
400 blood sample. As demonstrated in the previous sections, it is not possible to unambiguously
401 identify an unknown blood sample as healthy, disease or trait by treating it with just a single
402 concentration of sodium metabisulphite. Therefore, we treat each unknown sample with both 0.1%
403 and 0.3% sodium metabisulphite and plot the corresponding P_1 and P_2 values. As healthy RBCs
404 do not sickle with either concentration, P_1 and P_2 are low, and the corresponding points (hollow
405 and solid black squares) lie in the grey region below the classifier. In contrast, more than 80%
406 RBCs in disease samples sickle when treated with either 0.1% or 0.3% sodium metabisulphite,
407 resulting in high P_1 and P_2 values. Hence, both points (hollow and solid red circles) corresponding
408 to disease samples lie in the white region above the classifier. As very few RBCs in trait samples
409 sickle when treated with 0.1% sodium metabisulphite, the corresponding point (solid blue triangle)
410 lies below the classifier. The same trait sample has high P_1 and P_2 values when treated with 0.3%
411 sodium metabisulphite. Therefore, the corresponding point (hollow blue triangle) lies above the
412 classifier.



413

414 *Figure 6. A classification scheme to unambiguously distinguish between disease, trait and healthy blood*
415 *samples. (A) Workflow to classify an unknown sample. Each unknown sample is treated with two different*
416 *sodium metabisulphite concentrations (0.1% and 0.3%) and imaged after 30 min. (B) P_2 vs. P_1 plots for*
417 *healthy, disease and trait samples. Solid and hollow symbols correspond to 0.1% and 0.3% sodium*
418 *metabisulphite respectively. For a healthy sample both points lie below the classifier (grey region). For a*
419 *disease sample, both points lie above the classifier (white region). For a trait sample, the point*
420 *corresponding to 0.1% sodium metabisulphite lies below the classifier, while the point corresponding to*
421 *0.3% sodium metabisulphite lies above the classifier. (C) Our technique accurately classified 35 distinct*
422 *unknown samples ($H = 10$; $D = 10$ and $T = 15$) as shown in the three plots.*

423 As shown in **figure 6B**, we validated the classification scheme in a pilot study where we accurately
424 identified thirty-five unknown blood samples (H = 10, D = 10 and T = 15) from adults and older
425 children. We also compared the performance of this classifier with the other classifier (combination
426 #12) identified from the connectivity-Dunn index plot. As shown in **figure S8** in the supporting
427 information, this classifier too could correctly identify all 35 unknown samples. This is the first
428 proof of concept demonstrating RBC shape as the sole biophysical parameter to distinguish
429 between sickle homozygous (disease) and heterozygous (trait) blood samples with high accuracy.
430 However, this technique is yet to be validated with other hemoglobin variants or blood samples
431 obtained from newborns with high levels of fetal hemoglobin.

432 **Conclusion**

433 We demonstrated a microscopy technique for confirmed diagnosis of sickle cell disease in less
434 than an hour that could be a potential gamechanger in resource-challenged settings by
435 distinguishing between sickle cell disease patients who need immediate clinical intervention (e.g.,
436 treatment) and carriers who need non-clinical intervention (e.g., counselling). This technique can
437 change the paradigm of the current two-step diagnosis protocol by exploiting the differential
438 polymerization of hemoglobin in disease and trait blood under controlled hypoxic conditions in a
439 microfluidic chamber and using it to conclusively discriminate between these samples by
440 microscopy alone. Using this technique, we correctly identified 35 blood samples as healthy, sickle
441 cell disease or trait. We built an extremely robust portable smartphone microscope to perform our
442 test in multiple remote field locations. The GPS feature of the smartphone can be utilized for
443 recording the location of new patients. This feature also makes it the only diagnostic technique
444 with built-in disease mapping. Due to faster confirmed results, our test can improve patient
445 compliance to screening efforts and reduce the burden on HPLC systems. The test needs just a
446 drop of blood instead of 2 - 4 ml of venous blood collected for HPLC. While this study was
447 designed for testing blood samples from older children and adults, it is particularly suitable for
448 newborns where only a small volume of blood from a heel-prick is available.

449

450 **Data availability statement**

451 The main data from which conclusions are drawn are included in the manuscript and the supporting
452 information. Suitably de-identified images of blood samples are available for research and teaching
453 purposes from the corresponding author on request.

454

455 **Code availability statement**

456 All codes used for analyzing images and processing the data can be found at the following link.
457 <https://github.com/ridz46/SickleCellDataAnalysis>

458

459 References

- 460 (1) Barabino, G. A.; Platt, M. O.; Kaul, D. K. Sick Cell Biomechanics. *Annu. Rev. Biomed.*
461 *Eng.* **2010**, *12*, 345–367. <https://doi.org/10.1146/annurev-bioeng-070909-105339>.
- 462 (2) Ware, R. E. Is Sick Cell Anemia a Neglected Tropical Disease? *PLoS Negl. Trop. Dis.*
463 **2013**, *7* (5), 5–8. <https://doi.org/10.1371/journal.pntd.0002120>.
- 464 (3) McGann, P. T. Time to Invest in Sick Cell Anemia as a Global Health Priority. *Pediatrics*
465 **2016**, *137* (6). <https://doi.org/10.1542/peds.2016-0348>.
- 466 (4) Williams, T. N. An Accurate and Affordable Test for the Rapid Diagnosis of Sick Cell
467 Disease Could Revolutionize the Outlook for Affected Children Born in Resource-Limited
468 Settings. *BMC Med.* **2015**, *13* (1), 1–3. <https://doi.org/10.1186/s12916-015-0483-4>.
- 469 (5) Ilyas, S.; Simonson, A. E.; Asghar, W. Emerging Point-of-Care Technologies for Sick Cell
470 Disease Diagnostics. *Clin. Chim. Acta* **2020**, *501* (October 2019), 85–91.
471 <https://doi.org/10.1016/j.cca.2019.10.025>.
- 472 (6) Sherman, I. J. The Sickling Phenomenon, with Special Reference to the Differentiation of
473 Sick Cell Anemia from Sick Cell Trait. *Bull. Johns Hopkins Hosp.* **1940**, *67*, 309–324.
- 474 (7) Daland, G. A.; Castle, W. B. A Simple and Rapid Method for Demonstrating Sickling of the
475 Red Blood Cells the Use of Reducing Agents. *J. Lab. Clin. Med.* **1948**, *3* (9), 1082–1088.
- 476 (8) Itano, H. A.; Pauling, L. A Rapid Diagnostic Test for Sick Cell Anemia. *Blood* **1949**, *4* (1),
477 66–68. <https://doi.org/10.1182/blood.v4.1.66.66>.
- 478 (9) Delgado-Font, W.; Escobedo-Nicot, M.; González-Hidalgo, M.; Herold-Garcia, S.; Jaume-
479 i-Capó, A.; Mir, A. Diagnosis Support of Sick Cell Anemia by Classifying Red Blood Cell
480 Shape in Peripheral Blood Images. *Med. Biol. Eng. Comput.* **2020**, *58* (6), 1265–1284.
481 <https://doi.org/10.1007/s11517-019-02085-9>.
- 482 (10) Praljak, N.; Iram, S.; Goreke, U.; Singh, G.; Hill, A.; Gurkan, U. A.; Hinczewski, M.
483 Integrating Deep Learning with Microfluidics for Biophysical Classification of Sick Red
484 Blood Cells. *bioRxiv* **2020**, 2020.07.01.181545.
- 485 (11) Linus, P.; Harvey, A. I.; Singer, S. J.; Wells, I. C. Cell Anemia, a Molecular. *Science* (80-.).
486 **1949**, *110* (3), 543–548.
- 487 (12) Horiuchi, K.; Ballas, S. K.; Asakura, T. The Effect of Deoxygenation Rate on the Formation
488 of Irreversibly Sickled Cells. *Blood* **1988**, *71* (1), 46–51.
489 <https://doi.org/10.1182/blood.v71.1.46.46>.
- 490 (13) Horiuchi, K.; Ohata, J.; Hirano, Y.; Asakura, T. Morphologic Studies of Sick Erythrocytes
491 by Image Analysis. *Journal of Laboratory and Clinical Medicine.* **1990**, pp 613–620.
492 <https://doi.org/2341764>.
- 493 (14) Wheelless, L. L.; Robinson, R. D.; Lapets, O. P.; Cox, C.; Rubio, A.; Weintraub, M.;
494 Benjamin, L. J. Classification of Red Blood Cells as Normal, Sick, or Other Abnormal,
495 Using a Single Image Analysis Feature. *Cytometry* **1994**, *17* (2), 159–166.
496 <https://doi.org/10.1002/cyto.990170208>.
- 497 (15) Asakura, T.; Asakura, K.; Obata, K.; Mattiello, J.; Ballas, S. K. Blood Samples Collected
498 under Venous Oxygen Pressure from Patients with Sick Cell Disease Contain a Significant

- 499 Number of a New Type of Reversibly Sickled Cells: Constancy of the Percentage of Sickled
500 Cells in Individual Patients during Steady State. *Am. J. Hematol.* **2005**, *80* (4), 249–256.
501 <https://doi.org/10.1002/ajh.20468>.
- 502 (16) Das, D. K.; Chakraborty, C.; Mitra, B.; Maiti, A. K.; Ray, A. K. Quantitative Microscopy
503 Approach for Shape-Based Erythrocytes Characterization in Anaemia. *J. Microsc.* **2013**,
504 *249* (2), 136–149. <https://doi.org/10.1111/jmi.12002>.
- 505 (17) Jung, J.; Matemba, L. E.; Lee, K.; Kazyoba, P. E.; Yoon, J.; Massaga, J. J.; Kim, K.; Kim,
506 D. J.; Park, Y. Optical Characterization of Red Blood Cells from Individuals with Sickle
507 Cell Trait and Disease in Tanzania Using Quantitative Phase Imaging. *Sci. Rep.* **2016**, *6*
508 (July), 1–9. <https://doi.org/10.1038/srep31698>.
- 509 (18) Gual-Arnau, X.; Herold-García, S.; Simó, A. Erythrocyte Shape Classification Using
510 Integral-Geometry-Based Methods. *Med. Biol. Eng. Comput.* **2015**, *53* (7), 623–633.
511 <https://doi.org/10.1007/s11517-015-1267-x>.
- 512 (19) Javidi, B.; Markman, A.; Rawat, S.; O'Connor, T.; Anand, A.; Andemariam, B. Sickle Cell
513 Disease Diagnosis Based on Spatio-Temporal Cell Dynamics Analysis Using 3D Printed
514 Shearing Digital Holographic Microscopy. *Opt. Express* **2018**, *26* (10), 13614.
515 <https://doi.org/10.1364/oe.26.013614>.
- 516 (20) de Haan, K.; Ceylan Koydemir, H.; Rivenson, Y.; Tseng, D.; Van Dyne, E.; Bakic, L.;
517 Karınca, D.; Liang, K.; Ilango, M.; Gumustekin, E.; Ozcan, A. Automated Screening of
518 Sickle Cells Using a Smartphone-Based Microscope and Deep Learning. *npj Digit. Med.*
519 **2020**, *3* (1). <https://doi.org/10.1038/s41746-020-0282-y>.
- 520 (21) Schneider, C. A.; Rasband, W. S.; Eliceiri, K. W. NIH Image to ImageJ: 25 Years of Image
521 Analysis. *Nat. Methods* **2012**, *9* (7), 671–675. <https://doi.org/10.1038/nmeth.2089>.
- 522 (22) R-Core-Team. R: A Language and Environment for Statistical Computing. Vienna, Austria
523 **2013**.
- 524 (23) William, B.; Eaton, A. Hemoglobin S Gelation. *Blood* **1987**, *70* (5), 1245–1266.
- 525 (24) Mickols, W. E.; Corbetts, D.; Maestreel, F.; Tinoco, I. The Effect of Speed of Deoxygenation
526 on the Percentage of Aligned Hemoglobin in Sickle Cells. **1988**, 4338–4346.
- 527 (25) Corbett, J. D.; Mickols, W. E.; Maestre, M. F. Effect of Hemoglobin Concentration on
528 Nucleation and Polymer Formation in Sickle Red Blood Cells. *J. Biol. Chem.* **1995**, *270* (6),
529 2708–2715. <https://doi.org/10.1074/jbc.270.6.2708>.
- 530 (26) Pagana, K. D.; Pagana, T. J. *Mosby's Manual of Diagnostic and Laboratory Tests-E-Book*;
531 Elsevier Health Sciences, **2017**.
- 532 (27) Hofrichter, J. Kinetics of Sickle Hemoglobin Polymerization: II. A Double Nucleation
533 Mechanism. *J. Mol. Biol.* **1986**, *189* (3), 553–571. [https://doi.org/10.1016/0022-](https://doi.org/10.1016/0022-2836(86)90324-4)
534 [2836\(86\)90324-4](https://doi.org/10.1016/0022-2836(86)90324-4).
- 535 (28) Eaton, W. A.; Hofrichter, J. Sickle Cell Hemoglobin Polymerization. *Adv. Protein Chem.*
536 **1990**, *40* (C), 63–279. [https://doi.org/10.1016/S0065-3233\(08\)60287-9](https://doi.org/10.1016/S0065-3233(08)60287-9).
- 537 (29) Rotter, M.; Yosmanovich, D.; Briehl, R. W.; Kwong, S.; Ferrone, F. A. Nucleation of Sickle
538 Hemoglobin Mixed with Hemoglobin A: Experimental and Theoretical Studies of Hybrid-

- 539 Forming Mixtures. *Biophys. J.* **2011**, *101* (11), 2790–2797.
540 <https://doi.org/10.1016/j.bpj.2011.10.027>.
- 541 (30) Higgins, J. M.; Eddington, D. T.; Bhatia, S. N.; Mahadevan, L. Sickle Cell Vasooclusion
542 and Rescue in a Microfluidic Device. *Proc. Natl. Acad. Sci. U. S. A.* **2007**, *104* (51), 20496–
543 20500. <https://doi.org/10.1073/pnas.0707122105>.
- 544 (31) Alzubaidi, L.; Al-Shamma, O.; Fadhel, M. A.; Farhan, L.; Zhang, J. Classification of Red
545 Blood Cells in Sickle Cell Anemia Using Deep Convolutional Neural Network. *Adv. Intell.*
546 *Syst. Comput.* **2020**, *940*, 550–559. https://doi.org/10.1007/978-3-030-16657-1_51.
- 547 (32) Handl, J.; Knowles, J.; Kell, D. B. Computational Cluster Validation in Post-Genomic Data
548 Analysis. *Bioinformatics* **2005**, *21* (15), 3201–3212.
549 <https://doi.org/10.1093/bioinformatics/bti517>.

550

551 **Acknowledgements**

552 The authors would like to thank Sister Lavina, Sister Molly, Sister Monica, Mr. Bhavesh Raicha,
553 Mr. Manoj Parekh, the staff at Shirin and Jamshed Guzder Regional Blood Centre (Valsad), and
554 the staff at Dayanand Hospital (Talasari) for use of leftover blood samples and sharing of de-
555 identified HPLC results. They acknowledge Dr. G. Nageshwara Rao, Dr. Kanjaksha Ghosh, Dr.
556 Roshan Colah, Dr. Malay Mukherjee and Dr. Manisha Madkaikar for technical discussions, Dr.
557 Santosh Noronha for use of dissolved oxygen meter, and Mr. Devendra Dhaka, Mr. Binil Jacob,
558 Mr. Siddhant Jaitpal and Mr. Santosh Jinnawar for other technical and logistical support to the
559 project. This project was supported by a Grand Challenges Explorations (phase 1) grant from Bill
560 and Melinda Gates Foundation through their IKP-GCE program and a translation grant from Tata
561 Centre for Technology and Design (TCTD), Indian Institute of Technology Bombay. Riddha
562 Manna and Anish Mahto received salary support from a grant funded by the Wadhvani Research
563 Centre for Bioengineering (WRCB), Indian Institute of Technology Bombay. The authors are
564 grateful to Dr. Shamik Sen, Dr. Anirban Sain and Dr. Suchita Nath-Sain for their critical feedback
565 on the manuscript. Parts of figures 1, 2 and 6 were created with BioRender.com.

566

567 **Author contributions**

568 CD, OS, RM, MS, S, PG and DP designed research. YI provided sickle blood samples and the
569 HPLC results. CD, OS, RM, MS, S, SS, AM, PG, NM, and SS performed research. CD, OS, RM,
570 SS, AM, PG, SS and DP analyzed data. R.M., C.D., O.S., P.G. and D.P. wrote the paper. CD and
571 OS contributed equally to this work.

Differential sensitivity to hypoxia enables shape-based classification of sickle cell disease and trait blood samples

Claudy D'Costa, Oshin Sharma, Riddha Manna, Minakshi Singh, Samrat, Srushti Singh, Anish Mahto, Pratiksha Govil, Sampath Satti, Ninad Mehendale, Yazdi Italia and Debjani Paul

Supporting information

1. Design and development of an inverted portable smartphone microscope




Figure S1. An inverted single-objective portable smartphone microscope. Photos of the microscope models with fixed viewing angle (A) and adjustable viewing angle (B). (C) Ray diagram showing the light path inside both microscopes. (D) and (E) show the exploded 3D schematic of the mechanical parts of (A) and (B) respectively, while (F) and (G) show the corresponding optical systems.

Figure S1 shows the details of the portable and battery-operated single-objective microscope that we developed. **Figure S1(A)** shows the microscope model where the mobile phone holder is attached to the microscope body at a fixed angle, while the phone holder can be adjusted by any angle from 0° to 90° in the model shown in **Figure S1(B)**. As shown in **figure S1(C)**, a 1W white LED, fitted with a collimating lens, acts as the illumination source. The light transmitted

from the microfluidic chip passes through a 40X (0.65 NA) air objective and falls on a right-angled prism (prism #1 in the figure), which bends the beam by 90°. Another right-angled prism (prism #2 in the figure) bends the beam by another 90° such that it falls on an eye-piece lens with 15X magnification. A total magnification of 600X (using a 40X objective and a 15X eye-piece) is achieved in our microscope over a tube length of 160 mm. The smartphone can be removed by the user when the microscope is not in use.

Figures S1(D) and S1(E) show the exploded views of the mechanical assembly inside (A) and (B) respectively. A microscope slide or a microfluidic chip is placed on the sample stage. The sample stage is attached to a second stage (called “Z-movement stage” in our diagram) capable of vertical movement in both models. This arrangement allows us to move the sample stage up or down by turning the focusing knob. Therefore, the sample stage, and not the objective, is moved while focusing the image in our design. The focusing knob has a pitch of 0.25 mm. The Z-movement stage is fixed to the base plate of the microscope. The entire focusing arrangement and the base plate are made of aluminium to make the microscope stable. The base plate also supports another metallic vertical arm containing the objective lens holder. While the mobile phone holder in (A) is fixed, a key feature of the mechanical system in (B) is the presence of a 3D-printed rotating arm containing the optical components and the smartphone holder. This arm can be rotated by any angle from 0° to 90° to change the viewing angle of the smartphone. The outer casing of the microscope is 3D-printed in PLA.

Figure S1(F) and S1(G) shows the optical components of (A) and (B) respectively. The system of two prisms makes the microscope design compact. In case of design (B), the rotating arm contains the second prism, the eye-piece and the mobile phone holder. The rotating arm is mounted in such a way that (i) the incident surface of the second prism always remains parallel to the emitting surface of the first prism during rotation, and (ii) the emitting surface of the second prism remains parallel to the eye-piece. The arm rotates in a plane orthogonal to the beam connecting the two prisms. The 3D-printed smartphone holder is detachable and we customized it to the specific mobile phone models. We used a 3D printed PLA cover for the eye-piece to have a fixed distance between the eye-piece and the smartphone camera such that a sharp and focused image forms on the phone screen. The smartphone holder slides onto a slot on the eye-piece cover and keeps the camera in perfect alignment with the rest of the optical system.

2. Workflow for image analysis of RBCs

RGB images captured by the smartphone are converted into 8-bit grayscale images. After background subtraction and automatic thresholding, morphological operations are performed to obtain the outlines of the RBCs. Using an area filter, we rule out RBCs with areas <500 pixels ($\sim 2.5 \mu\text{m}^2$) as possible debris > 7500 pixels ($\sim 9.8 \mu\text{m}^2$) as clusters of RBCs. The detailed steps in ImageJ are described below.

The captured image (1) is first cropped (2) to fit the field of view and converted into an 8-bit grayscale image (3). We then subtract the background with a rolling ball radius of 50 pixels (4). Next, we make the grayscale image into a binary one using the automatic thresholding

algorithm of ImageJ. The RBCs appear black on a white background (5). This binary image is then converted into a mask, to make the RBCs appear white against a black background (6).




Figure S2. Steps involved in image analysis are shown. The original image (1) is opened in ImageJ and the area of interest is cropped (2). Then image is converted into an 8-bit grayscale image (3) and its background is subtracted to bring the RBCs in the foreground (4). The image is then binarized (5) and converted into a binary mask (6) to get the RBCs as white particles. The holes in the particles are filled to fill the center of the unfocused part of biconcave RBCs (7). Then the RBCs are analyzed to get their solidity, roundness values and outlines. 8a shows the outlines of the RBCs when an area filter is applied to fit the RBC sizes, while 8b shows the outlines without an area filter.

On the masked binary image, we perform the operation ‘fill holes’ (7). This is required as the central part of the biconcave RBCs remain out of focus, making these RBCs appear doughnut-shaped in the binary image. We then analyze the particles (RBCs) to get a list of unique identifiers for each RBC and their shape descriptors including roundness and solidity. Next, we apply an area filter described earlier to exclude debris and connected cells (8a). The panel 8b shows the same cells without the area filter. We then apply a solidity cut-off, where all RBCs

with solidity <0.8 are excluded. The RBCs remaining after this step are used to plot the roundness distributions.

3. Deoxygenation rate depends on oxygen scavenger concentration

We plotted the dissolved oxygen concentration as a function of time for different sodium metabisulphite concentrations (**figure 3A** in the manuscript). We fitted each plot to an equation of the functional form $y = Ae^{-\frac{x}{\tau}} + B$, where y indicates the dissolved oxygen content (%) and x indicates time (min). **Table S1** shows the fitting parameters for each concentration.

Table S1: Fitting parameters to extract the decay time constant (τ) describing the decrease in dissolved oxygen present in RPMI-1640 for different concentrations of the oxygen scavenger sodium metabisulphite.

<i>Sodium metabisulphite</i>	0.1%	0.2%	0.3%	0.4%	0.5%
<i>A</i>	112.5	117.1	106.6	100.7	99.6
<i>B</i>	- 7.2	- 4.5	- 0.9	0.2	0.8
τ (min)	12.2	9.3	6.1	3.5	1.6

4. Choice of diluent and dilution factor





Figure S3. Images of RBCs with different dilutions. (A) Strong rouleaux formation is seen with undiluted blood. (B) There are too many RBCs at 5X dilution, making it difficult for an image processing program to distinguish individual cells. (C) A dilution of 20X gives a sufficient number of cells in the field of view. (D – F) Dilutions of 40X, 60X and 100X lead to very few cells in the field of view, making it difficult to obtain reliable statistical data.


The buffer used to dilute blood must keep RBCs under minimal osmotic stress to avoid crenation, while the dilution factor should ensure that there is an adequate number of RBCs in the field of view. We first diluted healthy RBCs using 0.9% normal saline (NS), 5% dextrose, 1X phosphate buffered saline (PBS) and cell culture media (RPMI-1640). 5% dextrose led to clumping of healthy RBCs and was discarded. Next, sodium metabisulfite solutions of appropriate concentrations as discussed in the manuscript were prepared in NS, PBS and RPMI-1640 and were added to whole blood from trait and disease patients. Compared to RPMI-1640, sickling in PBS and normal saline took 2-3 times longer. Therefore, we continued our study with RPMI-1640 as the diluent.

The dilution was adjusted in such a way that the cells do not form stacks in the imaging chamber. As seen in **figure S3**, whole blood showed strong rouleaux formation. There were too many RBCs present in the field of view with 5X diluted blood, making it difficult for the image processing program to identify individual RBCs. The cells were sparsely distributed for 20X and 40X dilutions. However, there were too few cells in the field of view when blood was diluted by 40X, 60X or 100X. Dilutions higher than 40X also showed an increase in crenation. Therefore, we decided to continue our experiments with 20X dilution.


5. Raw images of disease, trait and healthy samples treated with sodium metabisulphite for 30 min



Filename: D126_0.1_30min_20170106_212209




Filename: D126_0.3_30min_20170106_221552




Filename: T163_0.1_30min_20170331_010215



Filename: T163_0.3_30min_20170331_013525



Filename: N07_0.1_30min_20190311_131331



Filename: N07_0.3_30min_20190311_131210


Figure S4. Raw images of disease (A and B), trait (C and D) and healthy (E and F) samples treated with 0.1% (left column) and 0.3% (right column) sodium metabisulphite respectively. The red rectangles show the areas from which snippets were taken for figure 4A.

Figure S4 shows some representative raw images of disease, trait and healthy blood samples. The red rectangles show the areas that were used as snippets in figure 4 of the manuscript.

6. RBC shapes in disease samples treated with 0.1% sodium metabisulphite

When we treat a disease sample with 0.1% sodium metabisulphite, we see holly leaf and granular RBCs in addition to sickle RBCs, as discussed in the manuscript. An image of a representative disease sample was manually annotated by an experienced user in **figure S5**. We find that out of 282 RBCs in the field of view, there are 100 (35%) sickle, 76 (27%) holly leaf and 63 (22%) granular RBCs. There are also 33 unsickled (12%) RBCs and 10 (4%) RBCs that could not be categorized.

A



B




Figure S5. Image of the disease sample (D126) shown in figure S4(A) after manual annotation by an experienced user. (A) We see sickle (red rectangles), holly leaf (green rectangles), granular (yellow rectangles), unsickled (blue rectangles) and uncategorized (white rectangles) RBCs. (B) Three examples of each cell type are shown.

7. Choosing roundness (R) over form factor (FF) to characterize RBC shapes

We explored both roundness and form factor for characterising individual RBC shapes in our study. We imaged healthy blood samples and measured both these parameters using ImageJ for

RBCs that are very close to circular in shape. Note that the parameter ‘form factor’ (FF) reported by Wheelless and others is the same as the parameter ‘circularity’ (C) measured by ImageJ. Both R and FF range from 0 for elongated objects to 1 for perfect circles.




Figure S6: Comparing roundness and form factor for characterizing individual RBC shapes. An image of a healthy blood sample is shown. The circularity and roundness values of three apparently circular RBCs in this image are also shown. As expected, the roundness distribution of the healthy sample peaks at 0.9-1.0, while the form factor (measured as circularity by ImageJ) peaks at 0.8.

Figure S6 shows the image of a healthy blood sample. Three individual RBCs (numbered 112, 89 and 46) that appear circular in this image are shown separately with their corresponding shape parameters. While the roundness values of these RBCs are >0.9 , the form factor is ~ 0.7 . This is because the form factor formula uses the value of the measured perimeter, which is more sensitive to the pixels in the boundary of an object. Therefore, the use of form factor in our image analysis could introduce artifacts in the brightfield images of sickle cells that often have blurred boundaries. On the other hand, the formula for roundness uses the value of the major axis, which is not sensitive to the pixels at the boundary of an object. Therefore, we used roundness to describe the shapes of irregular objects such as sickle RBCs.

8. Image artifacts in healthy blood samples leading to tails in roundness distributions

Figure 4C of the manuscript shows that the roundness distributions of healthy samples have tails at values of $R < 0.8$. As shown in **figure S7**, this is due to the presence of specific artifacts such as RBCs lying sideways (left panel), crenated RBCs (middle panel) or two or more RBCs overlapping in such a way that the area and solidity filters cannot exclude them (right panel). Our area filter during image processing is chosen to ensure that most sickle cells, which are somewhat larger in area compared to healthy biconcave RBCs, are included in our analysis. This area filter cannot exclude these artifacts when dealing with healthy blood samples.

However, the presence of the artifacts does not affect our workflow as seen from the data presented in **figure 5** and **figure 6** of the manuscript.




Figure S7. Images of selected RBCs from a healthy sample (N03) showing RBCs lying sideways (left panel), crenated RBCs (middle panel) or overlapping RBCs (right panel).

9. P_1 and P_2 combinations used to construct the Dunn index vs. connectivity plot

Table S2: Parameters used to construct the Dunn index vs. connectivity plot.

Combination number	Window size	Roundness range for P_1	Roundness range for P_2	Connectivity	Dunn index
1	0.2	0.0 - 0.2	0.2 - 0.4	2.01	0.07
2	0.2	0.1 - 0.3	0.3 - 0.5	4.97	0.02
3	0.2	0.2 - 0.4	0.4 - 0.6	14.75	0.03
4	0.2	0.3 - 0.5	0.5 - 0.7	4.56	0.07
5	0.2	0.4 - 0.6	0.6 - 0.8	15.07	0.08
6	0.2	0.5 - 0.7	0.7 - 0.9	11.31	0.07
7	0.2	0.6 - 0.8	0.8 - 1.0	4.03	0.06
8	0.3	0.0 - 0.3	0.3 - 0.6	7.07	0.02
9	0.3	0.1 - 0.4	0.4 - 0.7	12.42	0.05
10	0.3	0.2 - 0.5	0.5 - 0.8	4.16	0.08
11	0.3	0.3 - 0.6	0.6 - 0.9	8.15	0.06
12	0.3	0.4 - 0.7	0.7 - 1.0	3.45	0.14
13	0.4	0.0 - 0.4	0.4 - 0.8	11.01	0.09
14	0.4	0.1 - 0.5	0.5 - 0.9	11.36	0.02
15	0.4	0.2 - 0.6	0.6 - 1.0	6.77	0.02
16	0.5	0.0 - 0.5	0.5 - 1.0	6.30	0.00

Table S2 lists the parameters used to plot the Dunn index and connectivity values for sixteen different combinations of P_1 and P_2 . We varied window widths from 0.2 to 0.5. Combination numbers 10 and 12 with window widths of 0.3 each indicate the most promising combinations and these were used to analyse the data of 35 unknown samples.

10. An alternate classification scheme




Figure S8. An alternate classifier based on the parameter values of P_1 : 0.4 – 0.7 and P_2 : 0.7 – 1.0. (A) In a plot of 164 known samples ($H = 49$, $D = 23$ and $T = 92$), the dotted line indicates the classifier that separates healthy and sickle blood samples. The white area in all the plots indicates the parameter space for healthy samples, while the grey area indicates the parameter space for sickle (disease and trait) samples. (B) Both points corresponding to a healthy sample treated with 0.1% and 0.3% sodium metabisulphite lie above the classifier, while the corresponding points for a disease sample lie below the classifier. The point corresponding to a trait sample treated with 0.1% sodium metabisulphite lies in the space (white area) for healthy samples. The point for a trait sample treated with 0.3% sodium metabisulphite lies in the sickle (grey) zone. (C-E) Validation data for healthy ($H = 10$), trait ($T = 15$) and disease ($D = 10$) samples. All 35 unknown samples were accurately identified by this classifier.

Figure S8 shows an alternate classification scheme given by combination #12 of P_1 and P_2 values. This classifier also classifies 35 unknown samples with 100% accuracy.

12. Captions of movies uploaded as supporting information

Movie 1: Sickling video of a disease sample treated with 0.1% sodium metabisulphite. The 30 min video has been sped up 29.5 times. The sample ID is D188.

Movie 2: Sickling video of a disease sample treated with 0.3% sodium metabisulphite. The 30 min video has been sped up 29.8 times. The sample ID is D188.

Movie 3: Sickling video of a trait sample treated with 0.1% sodium metabisulphite. The 30 min video has been sped up 29.5 times. The sample ID is T187.

Movie 4: Sickling video of a trait sample treated with 0.3% sodium metabisulphite. The 30 min video has been sped up 29.5 times. The sample ID is T